Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial

IMPORTANCE: There are no disease-modifying treatments for Alzheimer disease (AD), the most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic effects of β-amyloid in vitro and in animal models of AD, and is a credible repurposed treatment candidate. OBJECTIVE: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard, Robert, Zubko, Olga, Bradley, Rosie, Harper, Emma, Pank, Lynn, O’Brien, John, Fox, Chris, Tabet, Naji, Livingston, Gill, Bentham, Peter, McShane, Rupert, Burns, Alistair, Ritchie, Craig, Reeves, Suzanne, Lovestone, Simon, Ballard, Clive, Noble, Wendy, Nilforooshan, Ramin, Wilcock, Gordon, Gray, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865324/
https://www.ncbi.nlm.nih.gov/pubmed/31738372
http://dx.doi.org/10.1001/jamaneurol.2019.3762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865324/
https://www.ncbi.nlm.nih.gov/pubmed/31738372
http://dx.doi.org/10.1001/jamaneurol.2019.3762

Ejemplares similares